Document 0050
 DOCN  M95B0050
 TI    A pilot study on the efficacy of epiroprim against developmental stages
       of Toxoplasma gondii and Pneumocystis carinii in animal models.
 DT    9511
 AU    Mehlhorn H; Dankert W; Hartman PG; Then RL; Department of Parasitology,
       Ruhr University, Bochum, Germany.
 SO    Parasitol Res. 1995;81(4):296-301. Unique Identifier : AIDSLINE
       MED/95350110
 AB    The new bacteriocidal drug epiroprim (Ro-11-8958) was tested (alone or
       in combination with dapsone) on its efficacy against Toxoplasma gondii
       and Pneumocystis carinii in their hosts: laboratory mice and/or nude
       mice/rats, and was compared to the curative effects of the recent drugs
       of choice. The experiments clearly pointed out that epiroprim has
       significant effects on the reduction of both parasites when given alone.
       In combination with dapsone epiroprim led to a complete cure of
       toxoplasmosis in mice. This finding is of some importance for AIDS
       patients mostly suffering from bacteriosis and parasitosis at the same
       time.
 DE    Animal  Anti-Infective Agents/THERAPEUTIC USE  Antibiotics,
       Combined/THERAPEUTIC USE  Comparative Study  Dapsone/THERAPEUTIC USE
       Female  Folic Acid Antagonists/THERAPEUTIC USE  Male  Mice  Mice, Inbred
       Strains  Mice, Nude  Mice, SCID  Pilot Projects  Pneumocystis
       carinii/*DRUG EFFECTS  Pneumocystis carinii Infections/*DRUG THERAPY
       Pyrimethamine/THERAPEUTIC USE  Rats  Rats, Nude  Sodium
       Chloride/THERAPEUTIC USE  Sulfadiazine/THERAPEUTIC USE  Toxoplasma/*DRUG
       EFFECTS  Toxoplasmosis, Animal/*DRUG THERAPY  Trimethoprim/*ANALOGS &
       DERIVATIVES/ADMINISTRATION & DOSAGE/  THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).